Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
08/17/20174:15PMGLOBEEndoPredict® Receives Positive Coverage Decisions From Medicare and Anthem
SALT LAKE CITY, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Palmetto GBA, the Medicare contractor who oversees the MolDx program and Anthem, Inc., one of the largest private insurers in the country, have announced... More...>>
08/08/20174:05PMGLOBEMyriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results
Total Revenues of $200.5 Million Up 8 PercentGAAP Diluted EPS was $0.19 and Adjusted EPS of $0.30Record Hereditary Cancer Demand and 86 Percent of Revenue Under Long-Term ContractCompany Issues Fiscal Year 2018 and Fiscal First-Quarter 2018 Financial Guidance SALT LAKE CITY, Aug. 08, 2017 (GLOBE NEWSWIRE) --  Myriad Genetics... More...>>
07/28/201711:16AMGLOBEMyriad to Announce Fiscal Fourth-Quarter 2017 Financial Results on August 8, 2017
SALT LAKE CITY, July 28, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 8, 2017.  During the call, Mark C. Capone, president and CEO and Bryan... More...>>
06/19/20177:05AMGLOBEVirginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region
SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that Virginia (“Gina”) C. Drosos, president of Assurex Health, a wholly-owned subsidiary of Myriad Genetics, has received the EY Entrepreneur of the Year... More...>>
06/15/20177:05AMGLOBECrescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra® DA at the 2017 Annual European Congress ...
SALT LAKE CITY, June 15, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data from a meta-analysis of clinical studies and a registry demonstrating the ability of the Vectra® DA test to predict joint damage were presented at the... More...>>
06/08/20177:05AMGLOBECrescendo Bioscience Announces Six Studies with Vectra® DA Will Be Presented at the 2017 Annual European Congress of Rheumat...
SALT LAKE CITY, June 08, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra® DA test will be presented at the European League Against Rheumatism (EULAR) meeting being held June 14-17, 2017, in Madrid. ... More...>>
06/04/20177:30AMGLOBEMyriad’s BRACAnalysis CDx® Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olapar...
SALT LAKE CITY, June 04, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® companion diagnostic test successfully identified BRCA-mutated patients with HER2- metastatic breast cancer in the OlympiAD... More...>>
06/02/20174:05PMGLOBEMyriad Announces 17 Additional Health Insurance Plans Covering EndoPredict™
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans have announced positive coverage policies for EndoPredict. Recently, Blue Shield of California, Humana, Inc., and multiple... More...>>
06/02/20177:05AMGLOBEMyriad Genetics Announces Results from a Large 2,000 Patient Clinical Utility Study of Its myRisk® Hereditary Cancer Test at...
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from Study 005, a large 2,000 patient prospective study of the Myriad myRisk® Hereditary Cancer test, which will be featured in three poster presentations... More...>>
05/31/20174:05PMGLOBEMyriad Genetics to Present at the 2017 William Blair Growth Stock Conference
SALT LAKE CITY, May 31, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four... More...>>
05/30/20174:05PMGLOBEMyriad Genetics to Present at the 2017 Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, May 30, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 10:00 a.m. PDT on June 13, 2017, at... More...>>
05/18/20177:05AMGLOBEMyriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting
SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from seven studies at the 2017 American Society of Clinical Oncology (ASCO) annual meeting to be held June 2 to 6, 2016 in Chicago... More...>>
05/12/20177:05AMGLOBEMyriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer
SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are... More...>>
05/08/20173:03AMDJNDon't Give Up on Stock Buybacks, At Least Not Yet -- WSJ
The programs are no longer a sure thing -- but there's still an effect on value stocks By Mark Hulbert Stock buybacks are no longer considered an unambiguously good thing, for companies or investors. But investors might still be able to profit from them. As recently as the 1990s, the market typically celebrated a... More...>>
05/05/20177:05AMGLOBEMyriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
SALT LAKE CITY, May 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from four separate prostate cancer studies at the American Urological Association (AUA) 2017 Annual Meeting being held May 12-16... More...>>
05/02/20174:05PMGLOBEMyriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results
Third-Quarter 2017 Total Revenues of $196.9 MillionThird-Quarter 2017 GAAP Diluted EPS of $0.06 and Adjusted EPS of $0.27Company Increases Annual Revenue Guidance, Narrows Adjusted EPS Guidance SALT LAKE CITY, May 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics... More...>>
04/27/20177:05AMGLOBEMyriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with ...
SALT LAKE CITY and BOULDER, Colo., April 27, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis’ PARP inhibitor, Rubraca.  Financial terms of... More...>>
04/18/20174:05PMGLOBEMyriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017
SALT LAKE CITY, April 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017.  During the call, Mark C. Capone, president and CEO and Bryan... More...>>
04/17/20177:05AMGLOBEStudy Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database
SALT LAKE CITY, April 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data comparing BRCA1 and BRCA2 variant classifications between Myriad Genetics and a commonly used public genetic database was published in the journal... More...>>
04/06/20177:05AMGLOBEMyriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s Novel PARP Inhibitor, BG...
SALT LAKE CITY, April 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has entered into a companion diagnostic development collaboration with BeiGene, a clinical-stage biopharmaceutical company developing molecularly-targeted... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20170824 06:46:28